Gilead Sciences (GILD) is a beast!  This stock is bid as it is repricing on the back of the  blockbuster Hepatitis C drug, Solvaldi.  

Though short term overbought with a RSI at 83, we think GILD has more to run.  Stay tuned.

(click here if chart is not overbought)